San Francisco startup Framework Therapeutics is also working on an oral, the moment-day by day GLP-one drug called GSBR-1290—the drug surpassed Wall Road’s anticipations in June every time a mid-phase study showed regular weight loss of close to 6% and it strategies to start A different mid-stage trial toward the tip of the 12 months—that fou